<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:atom="http://www.w3.org/2005/Atom">

  <channel>

    <title><![CDATA[openPR - Aktuelle Pressemitteilungen: Crucell]]></title>
    <description><![CDATA[openPR.de – Pressemitteilungen kostenlos einstellen]]></description>
    <lastBuildDate>Sun, 10 May 2026 01:39:47 +0200</lastBuildDate>
    <link>https://www.openpr.de/</link>

    <atom:link href="https://www.openpr.de/rss/" rel="self" type="application/rss+xml" />


    <item>
        <guid isPermaLink="false">pm-57244</guid>
        <pubDate>Wed, 17 Aug 2005 09:48:57 +0200</pubDate>
        <title><![CDATA[Crucell and US Navy Sign Agreement to Test AdVac®-based Vaccine Against Anthrax and Plague]]></title>
        <description><![CDATA[ Leiden, The Netherlands, August 17, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center of the US Navy to construct AdVac®-based vaccines against anthrax and plague and test them in non-human primates. 
 
Like Ebola and Marburg, anthrax and plague are among the so-called ´Category A´ agents, which are considered by the Centers for Disease Control and Prevention (CDC) …]]></description>

    
    
        
    
        <link>https://www.openpr.de/news/57244/Crucell-and-US-Navy-Sign-Agreement-to-Test-AdVac-based-Vaccine-Against-Anthrax-and-Plague.html</link>
        <author><![CDATA[Crucell]]></author>

    </item>


    <item>
        <guid isPermaLink="false">pm-57159</guid>
        <pubDate>Tue, 16 Aug 2005 12:23:40 +0200</pubDate>
        <title><![CDATA[Crucell N.V.  (NL) - Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron]]></title>
        <description><![CDATA[ Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron 
 
Leiden, The Netherlands, August 16, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement for recombinant protein production with Chiron Corporation. This new agreement allows Chiron to evaluate the PER.C6® cell line for use in the manufacturing of Chiron´s prophylactic hepatitis C vaccine, which is currently in …]]></description>

    
    
        
    
        <link>https://www.openpr.de/news/57159/Crucell-N-V-NL-Crucell-and-DSM-Announce-PER-C6-Licensing-Agreement-with-Chiron.html</link>
        <author><![CDATA[Crucell]]></author>

    </item>


  </channel>
</rss>
